Efficacy Data Cushion Tysabri, Burnt By Safety Scare
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec weighs in on rumors of malignancies in trials of Tysabri rival cladribine.
You may also be interested in...
Side Effects Dampen Neurologists' Enthusiasm For Novel MS Drugs
With nearly a dozen new multiple sclerosis drugs in some phase of mid- to late-stage development – from the first oral options to infrequently administered biologics – the treatment paradigm for the debilitating disease appears on the cusp of significant change.
Side Effects Dampen Neurologists' Enthusiasm For Novel MS Drugs
With nearly a dozen new multiple sclerosis drugs in some phase of mid- to late-stage development – from the first oral options to infrequently administered biologics – the treatment paradigm for the debilitating disease appears on the cusp of significant change.
Side Effects Dampen Neurologists’ Enthusiasm For Novel MS Drugs
With nearly a dozen new multiple sclerosis drugs in some phase of mid- to late-stage development - from the first oral options to infrequently administered biologics - the treatment paradigm for the debilitating disease appears on the cusp of significant change